Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer

Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we sought to develop new del...

Descripción completa

Detalles Bibliográficos
Autores principales: Belz, Jodi E., Kumar, Rajiv, Baldwin, Paige, Ojo, Noelle Castilla, Leal, Ana S., Royce, Darlene B., Zhang, Di, van de Ven, Anne L., Liby, Karen T., Sridhar, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695017/
https://www.ncbi.nlm.nih.gov/pubmed/29158830
http://dx.doi.org/10.7150/thno.18563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695017/
https://www.ncbi.nlm.nih.gov/pubmed/29158830
http://dx.doi.org/10.7150/thno.18563

Ejemplares similares